BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pulmo BioTech Has Revealed That Its PulmoBind(TM) Pulmonary Vascular Diagnostic Product Candidate May Have Particular Applicability to Post Operative Patient Care and Diagnostics


6/29/2010 11:14:53 AM

NEW YORK, June 29, 2010 (GLOBE NEWSWIRE) -- "Pulmonary Embolism (PE) is a potentially fatal condition that occurs when a blood clot forms within the vascular system of the body, becoming detached and then lodged in the pulmonary circulatory system of the lungs. Lung tissue death occurs beyond the embolism and depending on the size of the embolism this can result in conditions ranging from shortness of breath to death. There are many different causes for PE, but one of the times that people are most vulnerable is after surgery. The nature of the surgery itself coupled with post-operative care and reduced mobility can potentially contribute to a patient experiencing PE. If the early experimental results of PulmoBind™ are confirmed by further experiments and clinical trials, then PulmoBind™, which is a simple non-invasive diagnostic test, could be of particular benefit to patients who have undergone surgical intervention." – Garry McCann, CEO, Pulmo BioTech Inc.

Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES